Epstein Secrets

s are all risk averse. None of them need to get rich; their goal is to stay rich. It's a big differen

buyers. We are going to make a lot of money." We lost 10% overnight on that trade. That's just one example of what is going on this year. Also, Mylan (MYL) was trying to buy Perrigo (PRGO) this year. It was a big deal. Mylan came in hostilely and Perrigo had no defenses. They went down to the

ust 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pric

challenge is set for 9/26/16, with a potential ruling in 1Q17; the lower court case is consolidated for all known generic filers, i.e., MNTA/Sandoz, Mylan, Dr. Reddy's, Synthon/Pfizer and Amneal. We note that both the IPR decision and the lower court ruling can be appealed. Amanda Ens EFTA00820342

ust 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pric

challenge is set for 9/26/16, with a potential ruling in 1Q17; the lower court case is consolidated for all known generic filers, i.e., MNTA/Sandoz, Mylan, Dr. Reddy's, Synthon/Pfizer and Amneal. We note that both the IPR decision and the lower court ruling can be appealed. EFTA00820351 Amanda Ens

25, 2016 at 9:35:43 AM EDT To: Richard Kahn c > Rich, With yesterday's weakness in healthcare on pric

challenge is set for 9/26/16, with a potential ruling in 1Q17; the lower court case is consolidated for all known generic filers, i.e., MNTA/Sandoz, Mylan, Dr. Reddy's, Synthon/Pfizer and Amneal. We note that both the IPR decision and the lower court ruling can be appealed. Amanda Ens Director Bank